Zymo Research Corporation and BluMaiden Biosciences are collaborating to provide end-to-end clinical trial analytics and reporting services based on the human microbiome. This partnership is poised to revolutionize clinical insight and decision-making in the pharmaceutical industry, with the goal of improving therapeutic efficacy and commercial longevity. The partnership combines Zymo Research’s expertise in sample preparation and next-generation sequencing with BluMaiden’s advanced bioinformatics capabilities through its proprietary KEYSTONE™ AI analytics platform to explore the human microbiome to discover clinical insights into health and disease. Create seamless solutions that can help you. These insights include, but are not limited to, endpoint optimization, predicting drug responders versus non-responders, and patient enrichment and stratification.
The joint service will cover all steps of human microbiome analysis, including fit-for-purpose sample collection, nucleic acid purification, next-generation sequencing, sophisticated bioinformatics data analysis, and detailed clinical trial reporting. The new service is designed to be applicable to the entire trial cohort across Phase 1, 2, 3, and 4 clinical trials and will apply to a wide range of disease indications and intervention modalities, including those where microbiome data analysis was not previously possible. You can. respected. While the report provides information for early pilot analyses, it is also applicable to subsequent pivotal Phase 2 and 3 clinical trials. Pharmaceutical services can also be applied retroactively by leveraging raw sequence data and metadata for reanalysis.
This comprehensive approach is designed to give pharmaceutical customers easy, affordable and rapid access to high-quality clinical insights, with the goal of accelerating time to market and extending the commercial life of therapeutics.
Dr. Keith Booher, Director of Research Services at Zymo Research Corporation, detailed the strategic importance of the partnership and each company’s efforts to advance microbiome-based discoveries. “By combining the strengths of Zymo Research with BluMaiden Biosciences, we are not only enhancing our service offering but also setting a new standard for microbiome data analysis. This collaboration allows us to deliver unparalleled levels of accuracy and efficiency and support our clients’ research with the most comprehensive insights.”
Dr. Damien Keogh, CEO and Director of BluMaiden Biosciences, also commented on the organization’s shared vision to support the pharmaceutical sector with complete solutions for human microbiome analysis. “We are excited to partner with Zymo Research to bring this innovative pharmaceutical service to the market,” said Keogh. Our joint commitment to excellence and innovation enables us to meet the high-quality and rapidly evolving requirements of the pharmaceutical sector, delivering novel applications of microbiome-based data and translating these insights into patient-specific clinical outcomes. “It will happen.”
The new pharmaceutical service will be available in both Europe and North America from the end of the third quarter of 2024. The two companies are confident that this collaboration will greatly benefit pharmaceutical companies and other companies developing new treatments.
